Rossotti, R.
92  Ergebnisse:
Personensuche X
?
 
?
 
?
3

Temporal trends of access to DAAs treatments for HCV in the..:

Pasulo, L. ; Aghemo, A. ; Rizzardini, G....
Digestive and Liver Disease.  50 (2018)  1 - p. 45-46 , 2018
 
?
 
?
6

Letter: sustained virological response and liver healing:

Rossotti, R. ; Garcia‐Fraile Fraile, L. J. ; Baiguera, C..
Alimentary Pharmacology & Therapeutics.  45 (2017)  8 - p. 1171-1173 , 2017
 
?
 
?
8

Clinical management of ESBL-producing Enterobacteriaceae: t..:

Rossotti, R. ; Orani, A.
European Journal of Clinical Microbiology & Infectious Diseases.  31 (2011)  7 - p. 1517-1522 , 2011
 
?
9

Is HCV elimination among persons living with HIV feasible? ..:

d'Arminio Monforte, A ; Tavelli, A ; Rossotti, R...
https://discovery.ucl.ac.uk/id/eprint/10177059/1/Liver%20International%20-%202023%20-%20d%20Arminio%20Monforte.pdf.  , 2023
 
?
 
?
11

Development and validation of a prediction model for tocili..:

Mussini, C ; Cozzi-Lepri, A ; Menozzi, M...
https://discovery.ucl.ac.uk/id/eprint/10123406/1/Development%20and%20validation%20of%20a%20prediction%20model%20for%20tocilizumab%20failure%20in%20hospitalized%20patients%20with%20SARS-CoV-2%20infection.pdf.  , 2021
 
?
12

Development and validation of a prediction model for tocili..:

Mussini C ; Cozzi-Lepri A ; Menozzi M...
info:eu-repo/semantics/altIdentifier/pmid/33621264.  , 2021
 
?
13

The impact of DAA-mediated HCV eradication on CD4+ and CD8+..:

Bandera A ; Lorenzini P ; Taramasso L...
info:eu-repo/semantics/altIdentifier/pmid/33600068.  , 2021
 
?
14

Effectiveness of infection-containment measures on SARS-CoV..:

Cento V ; Alteri C ; Merli M...
info:eu-repo/semantics/altIdentifier/pmid/33216817.  , 2020
 
1-15